Clinical proteomics: applications for prostate cancer biomarker discovery and detection

被引:45
|
作者
Petricoin, EF
Ornstein, DK
Liotta, LA
机构
[1] US FDA, Ctr Biol Evaluat & Res, NCI Clin Proteom Program, Off Cell & Gene Therapies, Bethesda, MD 20892 USA
[2] Univ Calif Irvine, Dept Urol, Irvine, CA USA
[3] US FDA, Pathol Lab, Clin Proteom Program, Ctr Canc Res,NCI,NIH, Bethesda, MD 20892 USA
关键词
protein microarray; mass spectrometry; diagnostics; biomarkers; proteomics; pattern recognition;
D O I
10.1016/j.urolonc.2004.04.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The science of proteomics comprises much more than simply generating lists of proteins that change in expression as a cause of or consequence of pathophysiology. The goal of proteomics should be to characterize the information flow through the intercellular protein circuitry that communicates with the extracellular microenvironment and then ultimately to the serum/plasma macroenvironment. Serum proteomic pattern diagnostics is a new type of proteomic concept in which patterns of ion signatures generated from high dimensional mass spectrometry data are used as diagnostic classifiers. This recent approach has exciting potential for clinical utility of diagnostic patterns because low molecular weight metabolites, peptides, and protein fragments may have higher accuracy than traditional biomarkers of cancer detection. Intriguingly, we now have discovered that this diagnostic information exists in a bound state, complexed with circulating highly abundant carrier proteins. These diagnostic fragments may one day be harvested by circulating nanoparticles, designed to absorb, enrich, and amplify the repertoire of diagnostic biomarkers generated-even at the critical, initial stages of carcinogenesis. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:322 / 328
页数:7
相关论文
共 50 条
  • [1] Proteomics in prostate cancer biomarker discovery
    Larkin, Samantha E. T.
    Zeidan, Bashar
    Taylor, Matthew G.
    Bickers, Bridget
    Al-Ruwaili, Jamal
    Aukim-Hastie, Claire
    Townsend, Paul A.
    [J]. EXPERT REVIEW OF PROTEOMICS, 2010, 7 (01) : 93 - 102
  • [2] Proteomics in translational cancer research: biomarker discovery for clinical applications
    Cho, William C. S.
    [J]. EXPERT REVIEW OF PROTEOMICS, 2014, 11 (02) : 131 - 133
  • [3] Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications
    de Wit, Meike
    Fijneman, Remond J. A.
    Verheul, Henk M. W.
    Meijer, Gerrit A.
    Jimenez, Connie R.
    [J]. CLINICAL BIOCHEMISTRY, 2013, 46 (06) : 466 - 479
  • [4] The role of proteomics in prostate cancer research: Biomarker discovery and validation
    Pin, Elisa
    Fredolini, Claudia
    Petricoin, Emanuel F., III
    [J]. CLINICAL BIOCHEMISTRY, 2013, 46 (06) : 524 - 538
  • [5] Prostate tissue proteomics for biomarker discovery
    Liu, BC
    Zheng, YX
    Xu, Y
    Bin, Y
    Lei, JY
    Richie, JP
    [J]. JOURNAL OF UROLOGY, 2003, 169 (04): : 53 - 53
  • [6] Clinical Proteomics for Cancer Biomarker Discovery and Therapeutic Targeting
    Krieg, Rene C.
    Paweletz, Cloud P.
    Liotta, Lance A.
    Petricoin, Emanuel F., III
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2002, 1 (04) : 263 - 272
  • [7] Clinical proteomics and biomarker discovery
    Johann, DJ
    McGuigan, MD
    Patel, AR
    Tomov, S
    Ross, S
    Conrads, TP
    Veenstra, TD
    Fishman, DA
    Whiteley, GR
    Petricoin, EF
    Liotta, LA
    [J]. CIRCULATING NUCLEIC ACIDS IN PLASMA/SERUM III AND SERUM PROTEOMICS, 2004, 1022 : 295 - 305
  • [8] Biomarker discovery and clinical proteomics
    Silberring, Jerzy
    Ciborowski, Pawel
    [J]. TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2010, 29 (02) : 128 - 140
  • [9] Proteomics for cancer biomarker discovery
    Srinivas, PR
    Verma, M
    Zhao, YM
    Srivastava, S
    [J]. CLINICAL CHEMISTRY, 2002, 48 (08) : 1160 - 1169
  • [10] Applications of urinary proteomics in biomarker discovery
    Chen Shao
    Yan Wang
    YouHe Gao
    [J]. Science China Life Sciences, 2011, 54 : 409 - 417